5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 18.05▲ | 18.21▲ | 18.21▲ | 17.43▲ | 18.62▼ |
MA10 | 17.80▲ | 17.98▲ | 17.98▲ | 17.72▲ | 18.43▼ |
MA20 | 18.12▲ | 18.24▲ | 18.22▲ | 18.36▼ | 17.93▲ |
MA50 | 18.36▲ | 17.96▲ | 17.93▲ | 18.28▼ | 19.03▼ |
MA100 | 18.15▲ | 19.13▼ | 19.51▼ | 17.78▲ | 21.89▼ |
MA200 | 20.01▼ | 20.17▼ | 21.03▼ | 18.80▼ | 25.91▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.012▲ | -0.021▼ | -0.010▼ | -0.121▼ | 0.141▲ |
RSI | 54.495▲ | 53.379▲ | 53.397▲ | 49.245▼ | 48.066▼ |
STOCH | 43.674 | 45.519 | 45.519 | 36.583 | 65.040 |
WILL %R | -28.039 | -28.039 | -28.039 | -28.067 | -38.998 |
CCI | 73.593 | 64.692 | 64.821 | 20.593 | -74.940 |
Wednesday, August 13, 2025 09:27 AM
PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint ...
|
Tuesday, August 12, 2025 04:20 AM
PureTech Announces the Launch of Celea Therapeutics with a Mission to Transform the Treatment of Respiratory Diseases ...
|
Tuesday, August 05, 2025 03:00 PM
VE202 was well tolerated, with no reports of treatment-related serious adverse events Additional analyses from COLLECTiVE202 to be shared in upcoming scientific forums Vedanta to focus resources ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 17.87 | 18.7762 | 17.87 | 18.01 | 2,412 |
14/08/25 | 17.84 | 17.841 | 17.50 | 17.50 | 5,409 |
13/08/25 | 18.14 | 18.20 | 15.21 | 16.99 | 13,846 |
12/08/25 | 17.24 | 17.50 | 17.17 | 17.50 | 6,186 |
11/08/25 | 17.40 | 17.40 | 17.10 | 17.15 | 4,920 |
08/08/25 | 17.85 | 17.86 | 17.25 | 17.25 | 2,313 |
07/08/25 | 18.03 | 18.03 | 17.69 | 17.95 | 3,237 |
06/08/25 | 18.37 | 18.37 | 18.26 | 18.26 | 797 |
05/08/25 | 18.277 | 18.277 | 18.277 | 18.277 | 0 |
04/08/25 | 18.27 | 18.2774 | 18.27 | 18.2774 | 1,078 |
|
|
||||
|
|
||||
|
|